



## Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

March 14, 2022

WALTHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in a fireside chat at the 32<sup>nd</sup> Annual Oppenheimer Healthcare Conference on March 15, 2022.

### 32<sup>nd</sup> Annual Oppenheimer Healthcare Conference

Format: Fireside Chat  
Date: Tuesday, March 15, 2022  
Time: 10:40 a.m. ET

[Webcast Link](#)

The live webcast and a replay of the fireside chat can be accessed under "[Events](#)" in the Investors section of the Viridian Therapeutics, Inc. website.

### About Viridian Therapeutics

[Viridian Therapeutics](#) is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies. Viridian's most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). Viridian's second product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

### Investor and Media Contact:

John Jordan  
Viridian Therapeutics  
Vice President, Investor Relations  
& Corporate Communications  
617-272-4691  
[IR@viridiantherapeutics.com](mailto:IR@viridiantherapeutics.com)